Review article: Human pepsins - Their multiplicity, function and role in reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 2, 2006, Pages 2-9

  Roberts, N B ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ASPARTIC ACID; ASPARTIC PROTEINASE; CATHEPSIN D; CATHEPSIN E; COLLAGEN; GASTRICSIN; GASTRIN; PENTAGASTRIN; PEPSIN 1; PEPSIN 3B; PEPSIN 5; PEPSIN A; PEPSINOGEN; PEPSINOGEN II; PEPSTATIN; UNCLASSIFIED DRUG;

ACIDITY; AGAR GEL ELECTROPHORESIS; DIGESTION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; ENZYME SUBSTRATE COMPLEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REFLUX ESOPHAGITIS; REVIEW; STOMACH JUICE;

EID: 33747597566     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03038.x     Document Type: Review

References (65)

1. Cooper JB. Aspartic proteinases in disease: a structural perspective. Curr Drug Targets 2002; 3: 155-173.
2. Tang J. Aspartic peptidases. In: Barrett AJ, Rawlings ND, Woessner JF, eds. Handbook of Proteolytic Enzymes. London: Academic Press, 1998: 805-820.
3. Kageyama T. Pepsinogens, progastricsins and prochymosins: structure, function, evolution and development. Cell Mol Life Sci 2002; 59: 288-306.
4. Samloff IM. Cellular localisation of group1 pepsinogens in human gastric mucosa by immnofluorescence. Gastroenterology 1971; 61: 185-188.
5. Taylor WH. Biochemistry of the pepsins. In: Code CF, Heide W, eds. Handbook of Physiology-Alimentary Canal, vol V. Baltimore: Williams & Wilkins, 1968: 2567-2587.
6. Sepulveda P, Marciniszyn J, Liu D, Tang J. Primary structure of porcine pepsin. J Biol Chem 1975; 250: 5082-5088.
7. Tarasova N, Denslow ND, Parten BF, et al. A comparative study on amino-acid sequences of three major isoforms of human pepsin a. In: Takahashi K, ed. Aspartic Proteinsaes: Structure, Function, Biology and Biomedical Implications. New York: Plenum Press, 1995: 77-81.
8. Etherington DJ, Taylor WH. Nomenclature of the pepsins. Nature 1967; 216: 279-280.
9. Samloff SM. Slow moving protease and the seven pepsinogens. Electrophoretic demonstration of the existence of eight proteolytic fractions in human gastric mucosa. Gastroenterology 1969; 57: 659-669.
10. Walker V, Taylor WH. Pepsin 1 secretion in chronic peptic ulceration. Gut 1980; 21, 766-771.
11. Roberts NB, Taylor WH. The isolation and properties of a non-pepsin proteinase from human gastric mucosa. Biochem J 1978; 169: 617-624.
12. Etherington DJ, Taylor WH. The proteinases of human gastric adenocarcinomata. Clin Sci 1972; 42: 79-90.
13. Tang J, Wolf S, Caputto R, Trucco RE. Isolation and crystallization of gastricsin from human gastric juice. J Biol Chem 1959; 234: 1174-1178.
14. Jones AT, Balan KK, Jenkins SA, Sutton R, Critchley M, Roberts NB. Assay of gastricsin and individual pepsins in human gastric juice. J Clin Pathol 1993; 46: 254-258.
15. Green BN, Jones AT, Roberts NB. Electrospray mass spectrometric evidence for the occurrence of two major variants in native pig pepsin A. Biochem J 1996; 313: 241-244.
16. Yamagata Z, Zhang Y, Shinozaki S, et al. Influence of pepsinogen gene polymorphisms on serum pepsinogen. Ann Hum Genet 1997; 61: 93-97.
17. Joffe SN, Roberts NB, Taylor WH, Baron JH. Exogenous and endogenous acid and pepsins in the pathogenesis of duodenal ulcers in the rat. Dig Dis and Sci 1980; 25: 837-841.
18. Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic & Clin Pharmac Toxicol 2005; 96: 94-102.
19. Voynick IM, Fruton JS. The comparative properties of acid proteinases. Proc Nat Acad Sci 1971; 68: 257-259
20. Will P, Allbee WE, Witt CG, Bertko RJ, Gingella TS. Quantification of pig pepsin A in canine and rat gastric juice with the chromogenic substrate azocoll. Clin Chem 1984; 30: 707-711.
21. Hutton DA, Pearson JP, Allen A, Foster SNE. Mucolysis of the colonic mucus barrier by faecal proteinases: inhibition by interacting polyacrylate. Clin Sci 1990; 78: 265-271.
22. da Silva Gomes RA, Batista RP, Costa de Almedia A, Narcisco da Fonsceca D, Juliano L, Hial V. A fluorimetric method for the determination of pepsin activity. Anal Bioch 2003; 316: 11-14.
23. Walker V, Taylor WH. Pepsin 5 in gastric juice: determination and relationship to the alkali-stable activity. Gut 1979; 20: 977-982.
24. Roberts NB, Taylor WH. Comparative pepstatin inhibition studies on individual human pepsins and pepsinogens 1,3 and 5(gastricsin) and pig pepsin A. J Enz Inhib and Medic Chem 2003; 18: 209-217.
25. Walker V, Taylor WH. Ovalbumin digestion by human pepsins 1,3 and 5. Biochem J 1978; 176: 429-432.
26. Roberts NB, Taylor WH. Action of human pepsins 1,2,3 and 5 on the oxidised B-chain of insulin. Biochem J 1979; 179; 183-190.
27. Dunn BM. Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem Rev 2002; 102; 4431-4458.
28. Sampath-Kumar PS, Fruton JS. Studies on the extended active sites of acid proteinases. Proc Nat Ac Sci 1974; 71: 1070-7072.
29. Dash C, Kulkarni A, Dunn B, Rao M. Aspartic peptidase inhibitors: implications in drug development. Crit Rev Biochem Molec Biol 2003; 38: 89-119.
30. Brinkworth RI, Prociv P, Loukas A, Brindley PJ. Hemoglobin-degrading, aspartic protease of blood-feeding parasites. J Biol Chem 2001; 276: 38844-38851.
31. Gaw AJ, Williams LV, Spraggs CF, Jordan CC. Role of pepsin in the development of indomethacin-induced antral ulceration in the rat. Aliment Pharmac Therap 1995; 9: 167-172.
32. Dunn BM, Jimenez M, Parten BF, Valler MJ, Rolph CE, Kay J. A systematic series of synthetic chromophoric substrates for aspartic proteinases. Biochem J 1986; 237: 899-906.
33. Taylor WH. Studies on gastric proteolysis. 2. The nature of the enzyme-substrate interaction responsible for gastric proteolytic pH-activity curves with two maxima. Biochem J 1959; 71: 373-383.
34. Taylor WH. Studies on gastric proteolysis. 1 The proteolytic activity of human gastric juice and pig and calf gastric mucosal extracts below pH5. Biochem J 1959; 71: 73-79.
35. Taylor WH. Proteinases of the stomach in health and disease. Physiol Rev 1962; 42: 519-553.
36. Walker V, Taylor WH. Cigarette smoking, chronic peptic ulceration and pepsin 1 secretion. Gut 1979; 20: 971-976.
37. Etherington DJ, Taylor WH. The pepsins of normal human gastric juice. Biochem J 1969; 113: 663-668.
38. Peek K, Roberts NB, Taylor WH. The heterogeneity of human pepsin 1 as shown by high-performance ion-exchange chromatography. J Chromat 1989; 476: 291-297.
39. Ryle AP, Foltmann B. Human pepsins 1 and 2: heterogeneity and carbohydrate content. In: Kostka V, ed. Aspartate Proteinases and their Inhibitors. Berlin: Walter de Gruyter & Co., 1985: 97-101.
40. Pearson JP, Allen A, Roberts NB, Taylor NB. The carbohydrate component of human pepsin 1. Clin Sci 1987; 72(Suppl. 16): 33.
41. Etherington DJ, Taylor WH. The pepsins from human gastric mucosal extracts. Biochem J 1970; 118: 587-594.
42. Sali A, Matsumotor R, McNeil HP, Karplus M, Stevens RL. Three dimensional models of four mouse mast cell chymases. Identification of proteoglycan binding regions and protease-specific antigeneic epitopes. J Biol Chem 1993; 268: 9023-9034.
43. Walker V. Aspects of the Pathophysiology of the Pepsins. MD Thesis, Liverpool: The University of Liverpool, 1976.
44. Sheers R, Roberts NB. The effect of ranitidine and cimetidine on pentagastrin and insulin stimulated gastric secretion. Scand J Gastro 1981; 16 (Suppl. 69): 51-57.
45. Sheers R, Roberts NB. The effects of pirenzepine and ranitidine on pepsin secretion. In: Dotevall G, ed. Advances in gastroenterology with the selective antimuscarinic compound pirenzepine. London: Chapman Hall, 1982: 83-7.
46. Wright CI, Shaw B, Sanders DJ, Reed JD. Variation in the proportions of individual pepsins secreted by the cat in response to vagal stimulation and hypoglycaemia. Clin Sci and Molec Med 1975; 48: 297-305.
47. Hersey SJ. Pepsinogen secretion. In: Johnson LR, ed. Physiology of the Gastrointestinal Tract, 2nd edn. New York: Raven Press, 1987: 947-957.
48. Lanas AI, Anderson JW, Uemara N, Hischowitz BI. Effects of cholinergic, histaminergic and peptidergic stimulation on pepsinogen secretion by isolated human peptic cells. Scand J Gastro 1994; 29: 678-683.
49. Charpin-Elhamri G, Elbaba M, Descroix-Vagne M, Pansu D, Perret JP. Inhibitory effect of sorbin on pepsin secretion in conscious cats and rabbits. Peptides 2000; 21: 65-72.
50. Kordas K, Szalmay G, Pusztai A, Varga G. Phytohaemagglutinin inhibits gastric acid but not pepsin secretion in conscious rats. J Physiol Paris 2001; 95: 309-314.
51. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J of Gastro 2003; 98: 545-550.
52. Westerwald BD, Pals G, Defize J, et al. Pepsinogen A polymorphism in gastric mucosa and urine, with special reference to patients with gastric cancer. Clinical Genetics 1986; 30: 202-212.
53. Bebelman JP, Evers MPJ, Zelle B, et al. Family and population studies on the human pepsinogen A multigene family. Human Genet 1989; 82: 142-146.
54. Waft L, Roberts NB, Taylor WH. Hereditary aspects of duodenal ulceration: pepsin 1 secretion in relation to ABO blood groups and ABH secretor status. J Med Genet 1979; 16: 423-427.
55. Hirschowitz BI. A critical analysis with appropriate controls of gastric acid and pepsin secretion in clinical esophagitis. Gastro 1991; 101: 1149-1158.
56. Baxter ST. Factors in the Pathogenesis and Surgical Management of Gastrooesophageal Reflux Disease and their Contributions to Variability in Clinical Outcome. MD Thesis, Liverpool: The University of Liverpool, 2001.
57. Tobey NA, Hoseini SS, Caymaz-Bor C, Wyatt HR, Orlando GS, Orlando RC. The role of pepsin in acid injury to esophageal epithelium. Am J Gastro 2001; 96: 3062-3070
58. Nagahama K, Yamato M, Nishio H, Tekeuchi K. Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats. Dig Dis and Sci 2006; 51: 303-309.
59. Hirschowitz BI. Pepsin and the oesophagus. Yale J Biol Med 1999; 72: 133-143.
60. Coyle C. The Interaction of Alginates with Pepsins and other Proteins. Implications for the Treatment of Reflux Related Disorders. PhD Thesis, Liverpool: The University of Liverpool, 2006.
61. Gill GA, Johnston N, Buda A, et al. Laryngeal epithelial defenses against laryngopharyngeal reflux (LPR): investigations of E-cadherin, carbonic anhydrase isoenzyme 111 and pepsin. Ann Otol Rhinol Laryngol 2005; 114: 913-921.
62. Johnston N, Dettmar PW, Postma GN, et al. Effect of pepsin on laryngeal stress protein (SEP70, SEP 53 and HSP 70) response: role in laryngopharyngeal reflux disease. Ann Otol Rhinol Laryngol 2006; 115: 47-58.
63. Menges M, Muller M, Zeitz M. Increased acid and bile in Barrett's esophagus compared to reflux esophagitis and effect of proton pump inhibitor therapy. Am J Gastro 2001; 96: 331-337.
64. Castell DO, Richter JE, Vakil NB, Zuckerman S, Levine JG, Skammer W. Sustained heartburn resolution is a good predictor of subsequent symptom status in GERD patients with erosive esophagitis. Gut 2002; 51(Suppl.): A24.
65. Tang M, Dettmar P, Batchelor H. Bioadhesive oesophageal bandages: protection against acid and pepsin injury. Int J Pharmac 2005; 292: 169-177.